First PI3K Inhibitor to Improve Outcomes in HR+/HER2 − Breast Cancer

The SOLAR-1 trial tested whether the PI3K inhibitor alpelisib improved outcomes in HR+, HER2 − breast cancer patients.

Source: CancerNetwork - October 31, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news